| Literature DB >> 28060921 |
Elena Titova1,2, Øyvind Salvesen3, Signe Berit Bentsen4, Synnøve Sunde2, Sigurd Steinshamn1,2, Anne Hildur Henriksen1,2.
Abstract
BACKGROUND: Implementation of the COPD-Home integrated disease management (IDM) intervention at discharge after hospitalizations for acute exacerbations of COPD (AECOPD) led to reduced hospital utilization during the following 24 months compared to the year prior to study start. AIMS: To analyze the impact of the COPD-Home IDM intervention on health related quality of life, symptoms of anxiety and depression, and the degree of patient activation during 24 months of follow-up and to assess the association between these outcomes.Entities:
Mesh:
Year: 2017 PMID: 28060921 PMCID: PMC5218408 DOI: 10.1371/journal.pone.0167887
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Schematic presentation of participant and number of respondents in percent (%) to participants in the study during 24 months of follow-up.
IC: integrated care; UC: Usual care; SGRQ: the St.George’s Respiratory Questionnaire; HADS: the Hospital Anxiety and Depression Scale; PAM: the Patient Activation Measure.
Subjects´ and diseases´ characteristics at baseline.
| Variables | IC group | UC group | P-value | |
|---|---|---|---|---|
| Age, years, Mean (SD) | 73.6 (9.2) | 72.2 (9.4) | 0.38 | |
| Sex, n (%) | Male | 39 (42.9) | 34 (42.5) | 0.96 |
| Female | 52 (57.1) | 46 (57.5) | ||
| BMI, kg/m2, Mean (SD) | 22.7 (5.2) | 23.5 (6.0) | 0.55 | |
| FEV1 L/sec, Mean (SD) | 0.86 (0.36) | 0.84 (0.33) | 0.68 | |
| FEV1%, Mean (SD) | 33.6 (9.9) | 33.4 (9.4) | 0.92 | |
| GOLD3, n (%) | 54 (59.3) | 46 (58.5) | 0.81 | |
| GOLD 4, n (%) | 37 (40.7) | 34 (42.5) | ||
| Hospital admissions (number) year prior study: | 1 | 60 (65.9) | 46 (57.5) | 0.26 |
| 2–3 | 23 (25.3) | 23 (28.8) | 0.61 | |
| ≥4 | 8 (8.8) | 11 (13.8) | 0.30 | |
| Living alone n (%) | 47 (51.6) | 38 (47.5) | 0.58 | |
| Current smokers, n (%) | 30 (33.0) | 32 (40.0) | 0.46 | |
| Receiving home care, n (%) | 51 (56.0) | 41 (51.3) | 0.53 | |
| Charlson co morbidity Index | 1–3 | 18 (19.8) | 18 (22.5) | 0.87 |
| 4–6 | 57 (62.6) | 47 (58.8) | ||
| 7–10 | 16 (17.6) | 15 (18.8) | ||
| Inhaled medication, n (%) | LAMA | 20 (39.2) | 25(51) | 0.2 |
| LABA+ICS | 36 (70.6) | 35 (71.4) | 0.9 |
IC: integrated care; UC: usual care; BMI: body mass index; FEV1: forced expiratory volume in one second; FEV1%: FEV1% of predicted value; HA: hospital admission due to AECOPD one year prior study start; LAMA: long –acting muscarinic receptor antagonist; LABA: Long- acting β2-agonist; ICS: inhaled Corticosteroids.
The mean SGRQ, HADS, PAM scores and difference in score change over time.
| Mean scores (95%CI) | Mean difference in change between IC and UC groups (95%CI) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time points | T0 | T1 | T2 | T3 | T1 | T2 | T3 | |||||
| Group | IC | UC | IC | UC | IC | UC | IC | UC | ||||
| Total score | 57.3 | 63.2 | 53.6 (49.1 to 57.9) | 55.4 (50.0 to 60.8) | 56.5 (52.0 to 61.0) | 57.6 (52.3 to 63.0) | 53.2 (47.5 to 58.9) | 60.4 (53.7 to 67.1) | 2.3 (-2.6 to 7.2) | 4.9 (-1.0 to 11.0) | -1.2 (-7.8 to 5.3) | |
| Symptoms | 63.0 | 71.8 | 58.2 (53.0 to 63.4) | 60.3 (54.1 to 66.5) | 61.2 (55.6 to 66.8) | 66.2 (60.8 to 71.7) | 55.0 (48.2 to 62.0) | 65.8 (59.0 to 73.0) | 3.9(-3.4. to 11.3) | 2.9(-4.3 to 10.1) | -0.8 (-8.6 to 7.0) | |
| Activity | 76.8 (72.7 to 80.7) | 76.1 (70.5 to 81.7) | 72.6 (67.8 to 77.5) | 71.5 (65.7 to 77.2) | 74.6 (69.7 to 79.6) | 73.1 (67.2 to 79.0) | 72.4 (66.0 to 78.9) | 75.6 (68.5 to 82.5) | -0.1 (-6.5 to 6.2) | 0.6 (-7.9 to 6.6) | -5.7 (-13.0 to 1.5) | |
| Impacts | 46.4 (42.3 to 50.5) | 51.2 (46.1 to 56.3) | 41.5 (36.6. to 46.4) | 44.9 (39.1 to 50.8) | 45.5 (40.5 to 50.6) | 47.0 (41.4 to 52.7) | 42.2 (35.7 to 48.6) | 50.7 (43.6 to 57.8) | 1.5 (-3.9 to 6.9) | 4.8 (-1.8 to 11.4) | -1.4 (-8.9 to 6.0) | |
| 6.5 (5.46 to 7.4) | 7.2 (6.0 to 8.5) | 6.6 (5.5 to 7.6) | 6.4 (5.1 to 7.7) | 5.7 (4.7 to 6.6) | 7.2 (5.8 to 8.7) | 5.7 (4.4 to 6.9) | 7.1 (5.3 to 8.8) | 0.4 (-0.8 to 1.6) | -1.4 | -0.9 (-2.8 to 0.1) | ||
| 6.1 (5.4 to 6.7) | 6.0 (5.0 to 7.0) | 6.1 (5.2 to 6.9) | 6.3 (5.2 to 7.4) | 6.0 (5.0 to 7.0) | 6.5 (5.5 to 7.6) | 5.9 (3.9 to 7.9) | 5.0 (3.8 to 6.1) | -0.3 (-1.4 to 0.86) | -1.0 | 0.2 (-1.8 to 2.2) | ||
| 69.2 (66.0 to 72.3) | 66.7 (62.7 to 6.7) | 72.9 (69.6 to 76.2) | 71.3 (67.2 to 75.3) | 72.5 (68.7 to 76.2) | 70.4 (66.4 to 74.4) | 75.0 (70.4 to 79.7) | 71.0 (65.9 to 76.2) | 0.5 (-6.2 to 7.3) | 0.5 (-5.8 to 6.7) | 3.1 (-4.5 to 10.8) | ||
T0: baseline; T1: after 6 months of follow-up; T2: after 12 months of follow-up; T 3: after 24 months of follow-up; IC: integrated care; UC: usual care; SGRQ: The St. Georg’s Respiratory Questionnaire; HADS –A: the Hospital Anxiety and Depression Scale, score for Anxiety; HADS –D: the Hospital Anxiety and Depression Scale, score for Depression; PAM: the Patient Activation Measure;
a: statistically significant difference in Mean scores between IC and UC groups, p = 0.01 for Total score and p = 0.002 for Symptoms score;
b: statistically significant difference in mean score change between IC and UC groups, p = 0.02 for HADS-A and p = 0.03 for HADS-D.
Logistic regression analysis of lower patient activation measure (PAM) score.
| N = 148 | ||||
|---|---|---|---|---|
| Predictors | Odds Ratio | 95% Confidence interval for Odds Ratio | p-Value | |
| Lower | Upper | |||
| 1.02 | 0.96 | 1.07 | 0.48 | |
| 0.45 | 0.16 | 1.19 | 0.10 | |
| 3.07 | 1.15 | 8.15 | 0.02 | |
| 1.05 | 0.92 | 1.21 | 0.40 | |
| 1.22 | 1.03 | 1.45 | 0.02 | |
| 1.00 | 0.99 | 1.00 | 0.27 | |
HADS-A: the Hospital Anxiety and Depression Scale, score for Anxiety; HADS—D: the Hospital Anxiety and Depression Scale, score for Depression; Impact: Impact component of the St.George`s respiratory questionnaire